PICULiber8: Early Rehabilitation in Critically Ill Children - The PICU Liber8 Study

Sponsor
McMaster University (Other)
Overall Status
Completed
CT.gov ID
NCT03573479
Collaborator
London Health Sciences Centre (Other)
130
2
21.9
65
3

Study Details

Study Description

Brief Summary

This is a pilot quality improvement implementation study that will measure the impact of a rehabilitation bundle implementation on the outcomes of interest. Advancements in the care provided in Pediatric Intensive Care Units (PICUs) have led to fewer deaths in children. These improvements are unfortunately countered by the emergence of side effects of critical illness, known as PICU-acquired complications (PACs). Delirium, muscle weakness, drug dependency and withdrawal are increasingly common. PACs occur because children are often over-sedated and experience long periods of immobilization. PACs delay recovery, increase disability and worsen long-term function and quality-of-life. Although they are preventable, PACs are very common and frequently overlooked by clinicians. This study aims to "liberate"children from critical illness and improve their recovery and functioning after discharge, through an innovative rehabilitation bundle of 8 complementary steps (PICU Liber8) to reduce sedation, allow children to awaken and breathe comfortably, encourage early mobilization, and engage families in their child's care.

Condition or Disease Intervention/Treatment Phase
  • Other: PICU Liber8 Bundle

Detailed Description

This is a pilot quality improvement implementation study that will measure the impact of a rehabilitation bundle.

The objectives are:
  1. Primary - Implementation Objectives: to determine the feasibility and resources required to implement PICU Liber8 in 2 PICUs, evaluate strategies for successful bundle adoption. Co-Primary - Process Objectives: to determine the impact of PICU Liber8 on the process of care.

  2. Secondary Efficacy: impact on PACs and patient reported outcomes The methods consist of a PICU Liber8 Bundle Implementation Plan (Pronovost's 4 E's Framework), and measurement of the impact of Implementation through Orchestrated Testing (OT).

For successful adoption of the PICU Liber8 bundle, the following are necessary:
  1. A context appropriate implementation framework.

  2. An implementation team leader.

  3. Inter-professional team engagement (i.e. RN, RT, MD, pharmacy, allied health and family).

  4. Ability to customize PICU Liber8 to the needs of each site. We will use the Pronovost's implementation framework, which has been shown to facilitate successful bundle adoption and improve the quality of patient care in adult and pediatric ICUs.17-19 This framework has 4 phases: Engage, Educate, Execute and Evaluate.

Study Design

Study Type:
Observational
Actual Enrollment :
130 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Early Rehabilitation in Critically Ill Children - The PICU Lliber8 Study
Actual Study Start Date :
Jan 3, 2019
Actual Primary Completion Date :
Sep 30, 2020
Actual Study Completion Date :
Oct 30, 2020

Arms and Interventions

Arm Intervention/Treatment
Pre-implementation cohort

This is the pre-implementation phase where a baseline documentation will take place about usual clinical practice, perceptions and attitudes of PICU staff and clinicians

PICU Liber8 bundle

After the implementation of the bundle (the PICU Liber8 components) same measurements will be captured and analyzed comparatively.

Other: PICU Liber8 Bundle
Bundle of elements for quality improvement
Other Names:
  • implementation of strategy
  • Outcome Measures

    Primary Outcome Measures

    1. Completion rate of daily goals (compliance) [18 months]

      The total number and percentage of daily goals completed from a pre-established daily goals checklist that assess compliance with the bundle. This is considered part of the feasibility outcomes group.

    2. Performance of the bundle assessed with qualitative (i.e., narrative) description and comparison between groups. [18 months]

      Evaluation of performance as narrative description and comparison between periods of study, about the impact of the bundle on the process of quality of care. This also is part of the feasibility outcomes group.

    3. Perceptions about barriers and facilitators for implementation of the bundle [18 months]

      Qualitative (i.e., narrative) assessment, description, and comparison of the perceptions from key stakeholders (i.e., family members, patients, clinicians, administrative personnel, nurse team, etc.) between groups about perceived barriers and facilitators for the adequate bundle's implementation. This belongs to the acceptability outcome.

    Secondary Outcome Measures

    1. Economic analysis [18 months]

      Direct cost (in Canadian dollars) before and after the implementation of the bundle that measures activity-based costs associated with the implementation. Incremental costs of PICU associated complications will be added to this evaluation.

    2. Incidence of morbidities [18 months]

      Measured as the composite incidence (number of new cases) of either delirium, iatrogenic withdrawal, pressure ulcers, or PICU acquired weakness.

    3. Length of stay [1 month]

      Measured as total days in PICU and hospital, and hospital-free days at 30 days post PICU discharge.

    4. Ventilator-free days at 30 days [1 month]

      This is a clinically important outcome, measured as days using mechanical ventilation and days without it.

    5. 30-day mortality [18 months]

      Measured as the total number of deaths (due to any cause) during the PICU and/or hospital stay.

    6. Functionality [18 months]

      Using the Pediatric Evaluation and Disability Inventory-Computer Adaptive Test (PEDI-CAT), which measures abilities in three functional domains: Daily Activities, Mobility, and Social/Cognitive. The PEDI-CAT's Responsibility domain measures the extent to which the caregiver or child takes responsibility for managing complex, multi-step life tasks. A final score per several domains is calculated that ranges from 0 to 100.

    7. Health related quality of life [18 months]

      Using the Peds-QL, which includes four Scales (Physical Functioning, Emotional Functioning, Social Functioning, and School Functioning) that are grouped together on the actual questionnaire. The tool creates a final score from 0 to 100 (higher scores indicates better).

    8. Parental stress [18 months]

      Using the Pediatric Inventory for Parents, a 42 item score across 4 domains. Higher scores indicate greater frequency and difficulty.

    9. Risk measurement of psychological sequelae. [18 months]

      The risk of psychological sequelae will be measured with the Children's Critical Illness Impact Scale (CCIIS) for children >6 years of age, consisting of 23 items that result on the final scale (where higher scores are worse).

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    1 Month to 18 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No

    Inclusion criteria: All children admitted to the Pediatric Intensive Care Unit with a minimum of 48h stay in the PICU and more than one organ dysfunction.

    Exclusion criteria: as this is an assessment of a quality improvement strategy there are no criteria for excluding participants.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 McMaster Children's Hospital Hamilton Ontario Canada L8N 3Z5
    2 Children's Hospital London Health Sciences London Ontario Canada

    Sponsors and Collaborators

    • McMaster University
    • London Health Sciences Centre

    Investigators

    • Principal Investigator: Karen Choong, MD, MSc, McMaster University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Karen Choong, Professor, McMaster University
    ClinicalTrials.gov Identifier:
    NCT03573479
    Other Study ID Numbers:
    • PICULiber8/180409
    First Posted:
    Jun 29, 2018
    Last Update Posted:
    Feb 24, 2021
    Last Verified:
    Feb 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Karen Choong, Professor, McMaster University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 24, 2021